Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.
Oncology · Lancet Oncol · 2026-11-01
Guideline
Guo et al. Curative-intent management of de novo metastatic nasopharyngeal carcinoma: an evidence-based consensus guideline from the International Collaborating Oncology OrganisationsOncology · Lancet · 2026-10-26
RCTn = 299
Slomovitz et al. First-line pembrolizumab versus carboplatin plus paclitaxel in participants with mismatch repair-deficient advanced or recurrent endometrial cancer (KEYNOTE-C93/GOG-3064/ENGOT-en15): interim analysis of a multicentre, open-label, randomised, active-comparator controlled, phase 3 trialOncology · J Clin Oncol · 2026-10-08
RCTn = 42
Chugh et al. RINGSIDE Phase II Study of Varegacestat for Treatment of Desmoid Tumors: A Randomized Dose-Finding Clinical TrialOncology · J Clin Oncol · 2026-09-24
RCTn = 731
Peng et al. First-Line Retlirafusp Alfa Plus Chemotherapy for Human Epidermal Growth Factor Receptor 2-Negative Gastric or Gastroesophageal Junction Adenocarcinoma: A Randomized, Double-Blind, Phase III Study (RELIGHT)Oncology · J Clin Oncol · 2026-09-23
RCTn = 440
Ikeda et al. Five-Year Follow-Up of the Phase III ASCOT Trial of Adjuvant S-1 After Resection for Biliary Tract CancerOncology · J Clin Oncol · 2026-09-09
Secondary analysisn = 106
Subramanian et al. Personalized Circulating Tumor DNA Analysis for Predicting Outcomes and Tracking Response to Radiotherapy and Pembrolizumab in Localized Sarcomas: Analysis of the SU2C-SARC032 TrialOncology · Lancet Oncol · 2026-09-07
RCTn = 1,367
Vergote et al. Chemotherapy with or without pembrolizumab followed by maintenance pembrolizumab with or without olaparib as first-line treatment of patients with advanced BRCA non-mutated epithelial ovarian cancer (ENGOT-OV43/GOG-3036/KEYLYNK-001): a randomised, double-blind, placebo-controlled, phase 3 trialOncology · J Clin Oncol · 2026-09-03
RCTn = 436
Krämer et al. Molecularly Guided Therapy Versus Continued Chemotherapy in Unfavorable Cancer of Unknown Primary: Updated Efficacy and Safety From the Randomized, Phase II CUPISCO StudyOncology · Lancet Oncol · 2026-09-01
RCTn = 760
Kudo et al. Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 studyOncology · Ann Oncol · 2026-08-26
RCTn = 994
Haas et al. Adjuvant pembrolizumab for the treatment of clear cell renal cell carcinoma: five-year results from the phase III KEYNOTE-564 studyOncology · Lancet · 2026-08-22
RCTn = 201
Sun et al. Liver resection after atezolizumab and bevacizumab versus maintenance therapy for locally advanced hepatocellular carcinoma (TALENTOP): a multicentre, open-label, randomised, phase 3 trialOncology · Ann Oncol · 2026-08-21
RCTn = 760
Xu et al. Atezolizumab with or without tiragolumab in unresectable esophageal squamous-cell carcinoma following definitive concurrent chemoradiotherapy (SKYSCRAPER-07): a randomised, phase III study